新・血栓止血血管学 血管と血小板

出版社: 金芳堂
著者:
発行日: 2015-08-10
分野: 臨床医学:内科  >  血液
ISBN: 9784765316422
シリーズ: 新・血栓止血血管学
電子書籍版: 2015-08-10 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

7,040 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,040 円(税込)

商品紹介

本書は、最新の二光子顕微鏡による観察や細胞基盤型モデルにもとづく血栓の発生メカニズムなどをキャッチアップし、近年研究が著しく進んでいる血栓止血血管学の羅針盤となるべく編集された。また、血栓や止血についての理解は、血液の凝固因子の生化学的な作用だけでなく、血管の脈管形成や血管と神経の相互作用、血管と血液の物理的相互作用などの基礎的事実を踏まえてこそ進むと考える。そこで本書では、血小板と血管に着目した。血栓症と出血症の制圧のため、遺伝子から全身の脈管形成まで血管と血小板の動態を網羅した決定版である。

目次

  • 新・血栓止血血管学 血管と血小板

    ―目次―

    1部 血管
      1.血管病の分子病態:AVMを含むオーバービュー
      2.造血管幹細胞を維持する骨髄の微小環境(ニッチ)
      3.脈管形成(血管/リンパ管発生)
      4.神経と血管のワイアリング
      5.血管と血流の相互作用
      6.プロテアーゼ活性化受容体PAR
      7.血管新生
      8.動脈の構造と動脈硬化の病理
      9.メタボリック症候群と血栓症
      10.静脈血栓塞栓症の予防と治療
      11.末梢動脈閉塞症

    2部 血小板
      12.血小板と血栓:オーバービュー
      13.血小板産生のメカニズム
      14.血小板の超微細形態
      15.血小板機能と血流
      16.血小板反応とそのシグナル伝達機構
      17. 血栓形成制御とシミュレーション理論
      18. めでみる血栓形成過程:二光子顕微鏡の生体への応用
      19.先天性血小板異常症の今(先天性巨大血小板症を含む)
      20.ScramblaseとScott症候群
      21.von Willebrand病
      22.ADAMTS13
      23.TTPとaHUS
      24.ヘパリン起因性血小板減少症
      25.免疫性血小板減少症
      26.感染症と血小板
      27.白血球・血小板複合体(NETs)

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 止血機構と血栓症 オーバービュー

P.13 掲載の参考文献
1) 一瀬白帝. 緒言 : 21世紀の国民病 血栓症の制圧に向けて. 一瀬白帝編, 図説 血栓・止血・血管学-血栓症制圧のために-. 東京 : 中外医学社, 2005 ; 前付け.
15) Kasahara K, Kaneda M, Miki T, et al. Clot retraction is mediated by factor XIII-dependent fibrin-α IIbβ 3-myosin axis in platelet sphingomyelin-rich membrane rafts. Blood 2013 ; 122 : 3340-3348.

III 凝固線溶系因子の名称と国際疾病分類

P.26 掲載の参考文献
2) 一瀬白帝編. 図説 血栓・止血・血管学-血栓症制圧のために-. 中外医学社, 2005.
3) Blomback M, Abildgaard U, van den Besselaar AM, et al. Nomenclature of quantities and units in thrombosis and haemostasis (recommendation 1993). A Collaborative project of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH/SSC) and the Commission/Committee on Quantities and Units (in Clinical Chemistry) of the International Union of Pure and Applied Chemistry-International Federation of Clinical Chemistry (IUPAC-IFCC/CQU (CC)). Thromb Haemost 1994 ; 71 : 375-394.
4) 社団法人日本内科学会編. 内科学用語集 (第5版). 医学書院, 東京, 1998.
5) 日本医学会医学用語管理委員会編. 日本医学会医学用語辞典 英和 (第3版). 南山堂, 東京, 2007 (2013年6月より「医学会医学用語辞典Web版」が提供され, 2014年4月から一般公開されている).
6) 独立行政法人日本学術振興会. 文部科学省学術用語集医学編. 東京, 2003.
7) Uteg KH, Tausendfreund K. [Donor selection for the production of factor XIII preparations]. Folia Haematol Int Mag Klin Morphol Blutforsch 1985 ; 112 : 447-455.
9) Brackmann HH, Egbring R, Ferster A, et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma : a crossover randomised study. Thromb Haemost 1995 ; 74 : 622-625.
15) Frick PG. Hemophilia-like disease following pregnancy with transplacental transfer of an acquired circulating anticoagulant. Blood 1953 ; 8 : 598-608.
18) Brinkhous KM. A short history of hemophilia, with some comments on the word "Hemophilia." In : KM Brinkhous and HC Hemker, editors. Handbook of Hemophilia, Part 1, Amsterdam, New York : Excerpta Medica, American Elsevier Pub. Co. ; 1975, pp3-20.

IV 21世紀の研究と倫理 : 研究不正を防ぐために

P.32 掲載の参考文献
1) 香川知晶. 生命倫理の成立. 東京 : 勁草書房, 2000.
2) 文部科学省 科学技術・学術審議会 研究活動の不正行為に関する特別委員会. 研究活動の不正行為への対応のガイドラインについて-研究活動の不正行為に関する特別委員会報告書-. 2006. http://www.mext.go.jp/b_menu/shingi/gijyutu/gijyutu12/houkoku/_ics-Files/afieldfile/2013/05/07/1213547_001.pdf (2014/12/13閲覧)
3) 文部科学省科学技術政策研究所 第1調査研究グループ. 国立大学法人の財務分析. 2008. http://www.nistep.go.jp/achiev/ftx/jpn/mat150j/pdf/mat150j.pdf (2014/12/13閲覧)
4) 三宅康夫. 科学論文の捏造など研究における不正行為-その1 ショッキングな実情. Pharm Tech Japan 2008 ; 24 (1) : 67-75.
5) 三宅康夫. 科学論文の捏造など研究における不正行為-その2 研究活動における不正行為の背景と不正研究行為の防止. Pharm Tech Japan 2008 ; 24 (2) : 63-71.
6) 山崎茂明. 科学の不正行為と出版倫理. 実験医学 2003 ; 21 (7) : 944-947.
7) 文部科学省. 研究活動における不正行為への対応等に関するガイドライン . 2014. http://www.mext.go.jp/b_menu/houdou/26/08/_icsFiles/afieldfile/2014/08/26/1351568_02_1.pdf (2014/12/13閲覧)
8) 日本学術会議科学研究における健全性の向上に関する検討委員会. 提言 : 研究活動における不正の防止策と事後措置-科学の健全性向上ために-. 2013. http://www.scj.go.jp/ja/info/kohyo/pdf/kohyo-22-t131226.pdf (2014/12/13 閲覧)
9) 加藤浩. 研究活動における不正行為と法的規制. 薬学図書館 2014 ; 59 (3) : 196-203.
10) 松澤孝明. わが国における研究不正 : 公開情報の基づくマクロ分析 (2). 情報管理 2013 ; 56 (4) : 222-235.
11) 山崎茂明. 薬学領域における研究者倫理 : 利益相反を考えるために. 薬学図書館 2009 ; 54 (3) : 168-174.
12) 松澤孝明. わが国における研究不正 : 公開情報の基づくマクロ分析 (1). 情報管理 2013 ; 56 (3) : 156-165.

1部 血管

P.39 掲載の参考文献
P.47 掲載の参考文献
4) Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978 ; 4 : 7-25.
20) Miller CL, Rebel VI, Lemieux ME, et al. Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells. Exp Hematol 1996 ; 24 (2) : 185-194.
34) Mendez-Ferrer S, Michurina TV, Ferraro F,. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010 ; 466 : 829-834.
37) Omatsu Y, Seike M, Sugiyama T, et al. Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation. Nature2014 ; 508 (7497) : 536-540.
P.55 掲載の参考文献
8) Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002 ; 3 (3) : 411-423.
18) Suzuki-Inoue K, Inoue O, Ding G, et al. Essential in vivo roles of the C-type lectin receptor CLEC-2 : embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 2010 ; 285 (32) : 24494-24507.
P.63 掲載の参考文献
2) Va sudevan A, Long JE, Crandall JE, et al. Compartment-specific transcription factors orchestrate angiogenesis gradients in the embryonic brain. Nature Neuroscience 2008 ; 11 (4) : 429-439.
P.71 掲載の参考文献
2) Dobrin PB. Mechanical properties of arteries. In : Caro CG, Pedley TJ, Schroter RC, Seed WA, eds. The mechanics of the circulation. New York : Oxford University Press 1978 : 397.
13) Ando J, Korenaga R, Kamiya A. Flow-induced Endothelial Gene Regulation. In : Mechanical Forces and the Endothelium, edited by Lelkes, P.I. Singapore : harwood academic publishers, 1999 : 111-126.
20) O'Neil, R.G. and Heller, S. The mechanosensitive nature of TRPV channels. Pflugers Arch 2005 ; 451 : 193-203.
P.81 掲載の参考文献
5) Soh UJK, Dores MR, Chen B, et al. Signal transduction by protease ‐ activated receptors. Br J Pharmacol 2010 ; 160 (2) : 191-203.
9) Tricoci P, Huang Z, Held C, et al ; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Eng J Med 2012 ; 366 (1) : 20-33.
11) Morrow DA, Braunwald E, Bonaca MP, et al ; TRA2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events.N Eng J Med 2012 ; 366 (15) : 1404-1413.
12) 駒井太一. トロンビン受容体阻害薬. 内科 2012 ; 110 (1) : 74-78.
P.88 掲載の参考文献
P.95 掲載の参考文献
8) Imakita M, Yutani C, Strong JP, et al. Second nationwide study of atherosclerosis in infants, children and young adults in Japan. Atherosclerosis 2001 ; 155 : 487-497.
P.100 掲載の参考文献
25) 6) DeKeulenaer GW, Ushio-Fukai M, Yin Q, et al. Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-α-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000 ; 20 : 385-391.
P.109 掲載の参考文献
1) 小林隆夫編. 静脈血栓塞栓症ガイドブック改訂2版. 東京 : 中外医学社, 2010.
2) 小林隆夫. 静脈血栓塞栓症の予防対策. 日本臨牀 2014 ; 72 (7) : 1303-1308.
3) Sakuma M, Nakamura M, Yamada N, et al. Venous thromboembolism : deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J 2009 ; 73 (2) : 305-309.
4) 小嶋哲人, 太田覚史. 肺血栓塞栓症・深部静脈血栓症全国調査研究. In : 厚生労働省科学研究費補助金 難治性疾患克服研究事業「血液凝固異常症に関する調査研究」平成25年度総括・分担研究報告書. 2014 : 163-169.
5) 黒岩政之, 入田和男, 讃岐美智義, 他 . 2009-2011年周術期肺塞栓症調査結果から見た本邦における周術期肺血栓塞栓症の特徴. 麻酔 2013 ; 62 : 629-638.
7) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会. 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン. 東京 : メディカル フロント インターナショナル リミテッド, 2004.
8) 日本循環器学会合同研究班. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告) : 肺血栓塞栓症および深部静脈血栓症の診断・治療・予防に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf
10) National Institute for Health and Care Excellence. CG92 Venous thromboembolism - reducing the risk : understanding NICE guidance, 2010. http://www.nice.org.uk/guidance/CG92
11) 小林隆夫. 周産期における肺血栓塞栓症対策. 静岡県母性衛生学会学術雑誌 2011 ; 1 (1) : 3-10.
12) 小林隆夫. 研修コーナー. 妊産婦死亡報告からみた母体安全への提言 4) 肺血栓塞栓症. 日本産科婦人科学会誌 2012 ; 64 (9) 別冊 : N418-N424.
13) 公益社団法人日本産科婦人科学会, 公益社団法人日本産婦人科医会, 日本産婦人科・新生児血液学会, 他. ヘパリン在宅自己注射療法の適応と指針. 2011. http://www.jsognh.jp/common/files/society/demanding_paper_07.pdf
14) 小林隆夫. ガイドライン ここがポイント! ヘパリン在宅自己注射療法の適応と指針. Thrombosis Medicine 2013 ; 3 (4) : 71-75.
P.117 掲載の参考文献
2) 重松宏, 大城秀巳.【血栓症と抗血栓薬】血栓症の臨床疫学と臨床 閉塞性動脈硬化症 臨床像の変遷. Medicina (Mex) 2000 ; 37 : 728-730.
6) Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Vasc Surg 2000 ; 31 : S1-S296.
8) Haimovici H : Muscular, renal, and metabolic complications of acute arterial occlusions : Myonephropathicmetabolic syndrome. Surgery 1979 ; 85 : 461-468.
10) 藤岡顕太郎, 江里健輔, 中島伸之, 他. 間歇性跛行症例に対する薬効評価法 日本脈管学会間歇性跛行重症度評価小委員会報告. 脈管学 2000 ; 40 : 851-857.
12) Baigent C, Sudlow C, Collins R, et al. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002 ; 324 : 71-86.
13) Gent M, Beaumont D, Blanchard J, et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 ; 348 : 1329-1339.
17) 重松宏, 池田康夫, 石丸新, 他. 末梢閉塞性動脈疾患の治療ガイドライン . Circ J 2009 ; 73 (Suppl III) : 1507-1569.
18) Dorigo W, Pulli R, Piffaretti G, et al. Results from an Italian multicentric registry comparing heparinbonded ePTFE graft and autologous saphenous vein in below-knee femoro-popliteal bypasses. J Cardiovasc Surg (Torino) 2012 ; 53 : 187-194.
19) El-Sayed HF. Bypass surgery for lower extremity limb salvage : vein bypass. Methodist Debakey Cardiovasc J 2012 ; 8 : 37-42.

2部 血小板

P.130 掲載の参考文献
1) 内山真一郎. 虚血性脳血管障害. In : 池田康夫, 丸山征郎 (編). 血小板生物学, 東京 : メディカルレビュー社, 2004 : 675-694.
2) 内山真一郎. 血液凝固能. In : 橋本信夫 (編). 脳神経外科学体系, 東京 : 中山書店, 2004 : 32-44.
3) World Health Organization. Fact Sheets. Media Center 2014.
4) 内山真一郎. 健康に生きる. In : 矢崎義雄 (編). 医の未来, 東京 : 岩波書店, 2012 : 167-183.
6) 内山真一郎. アテローム血栓症の抗血小板療法を評価する. Vasc Med 2005 ; 1 : 53-62.
7) 内山真一郎. アスピリンの一次・二次予防効果のエビデンス. 薬局 2013 ; 64 : 276-284.
8) 杉本充彦. 血栓形成過程 : オーバービュー. J Jpn Coll Angiol 2011 ; 51 : 275-282.
11) 内山真一郎. 血小板活性化と血液凝血学的異常. 神経内科 2000 ; 52 : 10-17.
12) Grawaz M, Langer H, May AE. Platelet in inflammation and atherogenesis. J Clin Invest 2005 ; 115 : 3378-3384.
16) Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells evidence for a Gp IIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule-1 (ICAM-1), αvβ3 integrin, and GpIb α. J Exp Med 1998 ; 187 : 329-339.
27) 内山真一郎. 期待される抗血小板薬. 循環器内科 2010 ; 68 : 372-376.
28) Cattano M. New P2Y12 inhibitors. Circulation 2010 ; 121 : 171-179.
P.136 掲載の参考文献
4) Coller BS. A Brief History of ideas about platelets in health and disease. Platelets. ed. Michelson AD., Academic Press, xxiii-xii (i foreword), 2006
17) トロンボポエチン受容体作動薬のすべて, 東京, 先端医学社, 2012.
22) Martin F, Prandini MH, Thevenon D,et al. The transcription factor GATA-1 regulates the promoter activity of the platelet glycoprotein IIb gene. J Biol Chem 1993 ; 268 (29) : 21606-21612.
P.144 掲載の参考文献
2) White JG. Platelet structure. In : Michelson AD. ed. Platelets. IInd edition, Burlington, MA : Academic Press. 2006 : 45-73.
3) van Nispen tot Pannerden H, de Haas F, Geerts W, et al. The platelet interior revisited : electron tomography reveals tubular α -granule subtypes. Blood 2010 ; 116 : 1147-1156.
4) Urban D, Li L, Christensen H, et al. The VPS33Bbinding protein VPS16B is required in megakaryocyte and platelet α -granule biogenesis. Blood 2012 ; 120 : 5032-5040.
5) Peters CG, Michelson AD, Flaumenhaft R. Granule exocytosis is required for platelet spreading : differential sorting of α -granules expressing VAMP-7. Blood 2012 ; 120 : 199-206.
6) Maynard DM, Heijnen HF, Horne MK, et al. Proteomic analysis of platelet α-granules using mass spectrometry. J Thromb Haemost 2007 ; 5 : 1945-1955.
8) Nurden P, Poujol C, Winckler J, et al. Immunolocalization of P2Y1 and TPα receptors in platelets showed a major pool associated with the membranes of α-granules and the open canalicular system. Blood 203 ; 101 : 1400-1408.
9) Heijnen HF, Oorschot V, Sixma JJ, et al. Thrombin stimulates glucose transport in human platelets via the translocation of the glucose transporter GLUT-3 from α-granules to the cell surface. J Cell Biol 1997 ; 138 : 323-330.
10) Maynard DM, Heijnen HF, Gahl WA, et al. The α-granule proteome : novel proteins in normal and ghost granules in gray platelet syndrome. J Thromb Haemost 2010 ; 8 : 1786-1796.
17) Ebbeling L, Robertson C, McNicol A, et al. Rapid ultrastructural changes in the dense tubular system following platelet activation. Blood 1992 ; 80 : 718-723.
18) Hartwig JH. The platelet cytoskeleton. In : Michelson AD. ed. Platelets. IInd edition, Burlington, MA : Academic Press ; 2006 : 75-97.
22) 鈴木英紀. 血小板活性化とシグナル伝達. 顕微鏡 2005 ; 40 : 124-127.
25) Plow EF, Pesho MM, Ma Y. Integrin α IIbβ3. In : Michelson AD. ed. Platelets. IInd edition, Burlington, MA : Academic Press ; 2006 : 165-178.
26) Suzuki H, Yamazaki H, Tanoue K. Immunocytochemical studies on colocalization of α-granule membrane α IIb β 3 integrin and intragranular fibrinogen of human platelets and their cell-surface expression during the thrombin-induced release reaction. J Electron Microsc 2003 ; 52 : 183-195.
27) Kunishima S, Kashiwagi H, Otsu M, et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the α IIb β 3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 2011 ; 117 : 5479-5484.
28) Nurden AT, Pillois X, Fiore M, et al. Glanzmann thrombasthenia-like syndromes associated with macrothrombocytopenias and mutations in the genes encoding the α IIb β 3 integrin. Semin Thromb Hemost 2011 ; 37 : 698-706.
29) Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of α IIb β 3 : association with macrothrombocytopenia and glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med 2013 ; 1 : 77-86.
30) Kato K, Martinez C, Russell S, et al. Genetic deletion of mouse platelet glycoprotein Ibβ produces a Bernard-Soulier phenotype with increased α-granule size. Blood 2004 ; 104 : 2339-2344.
31) Watanabe R, Ishibashi T, Saitoh Y, et al. Bernardsoulier syndrome with a homozygous 13 base pair deletion in the signal peptide-coding region of the platelet glycoprotein Ibβ gene. Blood Coagul Fibrinolysis 2003 ; 14 : 387-394.
32) 鈴木英紀. 先天性血小板機能異常症/storage pool病. in坂田洋一, 小澤敬也, 編. 別冊・医学のあゆみ 血液疾患-state of arts Ver.3 ; 医歯薬出版 2005 : 733-736.
P.152 掲載の参考文献
2) Tsuji S, Sugimoto M, Miyata S, et al. Real-time analysis of mural thrombus formation in various platelet aggregation disorders : Distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood 1999 ; 94 : 968-975.
3) Sugimoto M, Tsuji S, Kuwahara M, et al. Sheardependent functions of the interaction between soluble von Willebrand factor and platelet glycoprotein Ib in mural thrombus formation on a collagen surface. Int J Hematol 1999 ; 69 : 48-53.
5) Kuwahara M, Sugimoto M, Tsuji S, et al. Cytosolic calcium changes in a process of platelet adhesion and cohesion on a von Willebrand factor-coated surface under flow conditions. Blood 1999 ; 94 : 1149-1155.
9) Hobbs, II WE, Lopez JA. Shear elegance : regulation of thrombus growth by shear stress. Blood 2008 ; 111 : 972.
P.157 掲載の参考文献
2) Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor clec-2 : From discovery to prospects. J Thromb Haemost 2011 ; 9 (Suppl 1) : 44-55.
9) 大森司. 抗血小板薬抵抗性の概念とその実態. 医学の歩み 2009 ; 228 : 1001-1006.
12) 田所誠司. 血小板インテグリンの負の調節因子. Annual Review血液 2013 ; 2013 : 175-181.
15) 井上克枝. 血小板の活性化と制御機構. 日本臨牀 2014 ; 72 : 1212-1217.
P.162 掲載の参考文献
1) 後藤信哉. 血小板細胞シミュレーションモデル. 日本血栓止血学会雑誌 2010 ; 21 : 334-336.
10) Miyazaki H, Yamaguchi T. Formation and destruction of primary thrombi under the influence of blood flow and von willebrand factor analyzed by a discrete element method. Biorheology 2003 ; 40 : 265-272.
P.168 掲載の参考文献
3) Nishimura S*, Takizawa H*,Takayama N, et al (*equal contribution). Lnk regulates integrin α IIb β 3 outside-in signaling in mouse platelets, leading to stabilization of thrombus development in vivo. J Clin Invest 2010 ; 120 (1) : 179-190.
5) Takizawa H, Nishimura S, Takayama N, et al. Lnk regulates integrin α IIb β 3 outside-in signaling in mouse platelets, leading to stabilization of thrombus development in vivo. J Clin Invest 2010 ; 120 (1) : 179-190.
P.178 掲載の参考文献
3) 柏木浩和, 冨山佳昭. 血小板機能異常症. In : 金倉譲, 冨山佳昭 (編). よくわかる血栓・止血異常の臨床. 初版. 中山書店 : 東京, 2014 : 92-104.
6) 國島伸治. 先天性血小板減少症の診断と分子病態. 臨床血液 2014 ; 55 : 882-892.
10) Ruiz C, Liu CY, Sun QH, et al. A point mutation in the cysteine-rich domain of glycoprotein ( GP) IIIa results in the expression of a GPIIb-IIIa (α IIbβ 3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 2001 ; 98 (8) : 2432-2441.
11) Fang J, Nurden P, North P, et al. C560Rβ 3 caused platelet integrin α II b β 3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. J Thromb Haemost 2013 ; 11 (6) : 1163-1171.
12) Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of α IIbβ 3 : association with macrothrombocytopenia and glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med 2013 ; 1 (2) : 77-86.
18) Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α -granules. Nat Genet 2011 ; 43 (8) : 732-734.
23) Whiteheart SW. α -Granules at the BEACH. Blood 2013 ; 122 (19) : 3247-3248.
30) Kunishima S, Kashiwagi H, Otsu M, et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the α IIbβ 3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 2011 ; 117 (20) : 5479-5484.
P.185 掲載の参考文献
5) Rukoyatkina N, Begonja AJ, Geiger J, et al. Phosphatidylserine surface expression and integrin α IIb β 3 activity on thrombin/convulxin stimulated platelets/particles of different sizes. Br J Haematol 2008 ; 144 : 591-602.
8) Miletich JP, Kane WH, Hofmann SL, et al. Deficiency of factor Xa-factor Va binding sites on the platelets of a patients with a bleeding disorder. Blood 1979 ; 54 : 1015-1022.
9) Rosing J, Bevers EM, Comfurius P, et al. Impaired factor X and prothrombin activation associated with decreased phospholipids exposure in platelets from a patient with a bleeding disorder. Blood 1985 ; 65 : 1557-1561.
10) Sims PJ, Wiedmer T, Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome : an isolated defect in platelet procoagulant activity. J Biol Chem 1989 ; 264 : 17049-17057.
12) Bevers EM, Wiedmer T, Comfurius P, et al. Defective Ca2+ -induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder : a study of the red blood cells of Scott syndrome. Blood 1992 ; 79 : 380-388.
15) Toti F, Satta N, Fressinaud E, et al. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 1996 ; 87 : 1409-1415.
P.194 掲載の参考文献
3) Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989 ; 264 : 19514-19527.
9) Rehemtulla A , Kaufman RJ. Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes. Blood 1992 ; 79 : 2349-2355.
14) Cramer EM, Meyer D, le Menn R, et al. Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood 1985 ; 66 : 710-713.
18) Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem 199 ; 266 : 8149-8155.
20) Fujimura Y, Titani K, Holland LZ, et al. von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986 ; 261 : 381-385.
23) Matsushita T, Meyer D, Sadler JE. Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. J Biol Chem 200 ; 275 : 11044-11049.
24) Lollar P, Hill-Eubanks DC, Parke CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988 ; 263 : 10451-10455.
25) Leyte A, van Schijndel HB, Niehrs C, et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991 ; 266 : 740-746.
28) Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994 ; 71 : 520-525.
29) von Willebrand factor Variant Database http://vwf.group.shef.ac.uk.
32) Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987 ; 69 : 1691-1695.
34) O'Brien LA, Sutherland JJ, Weaver DF, et al. Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations. J Thromb Haemost 2005 ; 3 : 796-797.
37) Rabinowitz I, Randi AM, Shindler KS, et al. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1993 ; 268 : 20497-20501.
38) Nishino M, Girma JP, Rothschild C, et al. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989 ; 74 : 1591-1599.
39) Mazurier C, Dieval J, Jorieux S, et al. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990 ; 75 : 20-26.
41) Mohri H, Motomura S, Kanamori H, et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998 ; 91 : 3623-3629.
43) Heyde E. Gastrointestinal Bleeding in Aortic Stenosis. NEJM 1958 ; 259 : 196-196.
45) Budde U, Scharf RE, Franke P, et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993 ; 82 : 1749-1757.
46) Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984 ; 64 : 981-985.
50) Lopez-Fernandez MF, Lopez-Berges C, Martin R, et al. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. Thromb Haemost 1987 ; 58 : 753-757.
P.202 掲載の参考文献
3) 藤村吉博, 松本雅則, 石西綾美, 他. 血栓性血小板減少性紫斑病. 臨床血液 2014 ; 55 : 93-104.
4) Moschcowitz E. Hyaline thombosis of the terminal arterioles and capillaries ; a hitherto undescribed disease. Proc NY Pathol Soc 1924 ; 24 : 21-24.
7) Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996 ; 87 : 4223-4234.
8) Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996 ; 87 : 4235-4244.
11) Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 ; 413 : 488-494.
P.211 掲載の参考文献
23) Stuhlinger W, Kourilsky O, Kanfer A, Sraer JD. Letter : Haemolytic-uraemic syndrome : evidence for intravascular C3 activation. Lancet 1974 ; 2 : 788-789.
24) Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clinical and experimental immunology 1981 ; 46 : 110-119.
26) Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. [Hemolytic-uremic syndrome : bilateral necrosis of the renal cortex in acute acquired hemolytic anemia.]. Schweiz Med Wochenschr 1955 ; 85 : 905-909.
29) 吉田瑤子, 藤村吉博. 非典型溶血性尿毒症症候群 (aHUS) の病態と治療戦略. 血液内科 2014 ; 69 : 589-594.
P.221 掲載の参考文献
4) Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992 ; 68 (1) : 95-96.
5) Greinacher A, Potzsch B, Amiral J, et al. Heparinassociated thrombocytopenia : isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994 ; 71 (2) : 247-251.
7) Warkentin TE, Greinacher A. Heparin-Induced Thrombocytopenia. 4th ed. New York : Informa Healthcare ; 2007.
39) Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000 ; 96 (5) : 1703-1708.
43) Greinacher A, Eichler P, Lubenow N, et al. Heparininduced thrombocytopenia with thromboembolic complications : meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000 ; 96 (3) : 846-851.
P.229 掲載の参考文献
7) George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura : a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 ; 88 : 3-40.
8) Brighton TA, Evans S, Castalidi PA, et al. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996 ; 88 : 194-201.
17) 藤村欣吾, 宮川義隆, 倉田義之, 他. 成人特発性血小板減少性紫斑病治療の参照ガイド2012年版. 臨床血液 2012 ; 53 : 433-442.
24) Amold DM, Dentali F, Crowther MA, et al. Systematic review : efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007 ; 146 : 25-33.
28) 宮川義隆, 柏木浩和, 高蓋寿朗, 他. 妊娠合併特発性血小板減少性紫斑病診療の参照ガイド. 臨床血液 2014 ; 55 : 934-947.
P.236 掲載の参考文献
4) Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al. Platelets : versatile effector cells in hemostasis, inflammation, and the immune continuum. Sem Immunopathol 2012 ; 34 (1) : 5-30.
14) Verschoor A, Neuenhahn M, Navarini AA, et al. A platelet-mediated system for shuttling blood-borne bacteria to CD8 α + dendritic cells depends on glycoprotein GPIb and complement C3. Nat Immunol 2011 ; 12 (12) : 1194-1201.
15) Elzey BD, Tian J, Jensen RJ, et al. Platelet-Mediated Modulation of Adaptive Immunity. Immunity ; 19 (1) : 9-19.
23) Grozovsky R, Begonja AJ, Liu K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 2014 ; doi : 10.1038/nm.3770.
P.241 掲載の参考文献
8) Mori Y, Yamaguchi M, Terao Y, et al. α -Enolase of Streptococcus pneumoniae induces formation of neutrophil extracellular traps. J Biol Chem. 2012 ; 287 (13) : 10472-10481.

最近チェックした商品履歴

Loading...